SEC 13F Intelligence

Altium Capital Management LLC / CRNX

Altium Capital Management LLC’s Crinetics Pharmaceuticals In Position

Does Altium Capital Management LLC own Crinetics Pharmaceuticals In (CRNX)? Not currently — the last reported position was 65.0K shares worth $2M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q4 2023
Shares
65.0K
% of Portfolio
+1.57%
Quarters Held
10
position exited

Position History CRNX

Reported value by quarter
Q4 ’20: $5MQ4 ’20Q1 ’21: $6MQ2 ’21: $10MQ2 ’21Q3 ’21: $4MQ4 ’21: $9MQ4 ’21Q1 ’22: $4MQ1 ’23: $2MQ1 ’23Q2 ’23: $2MQ3 ’23: $8MQ3 ’23Q4 ’23: $2Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q4 202365.0K$2M+1.57%
Q3 2023262.0K$8M+4.06%
Q2 2023135.0K$2M+1.84%
Q1 2023100.0K$2M+0.89%
Q1 2022204.0K$4M+1.50%
Q4 2021331.0K$9M+2.59%
Q3 2021193.0K$4M+1.07%
Q2 2021533.0K$10M+2.33%
Q1 2021361.9K$6M+1.54%
Q4 2020361.9K$5M+1.91%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Altium Capital Management LLC’s full portfolio or all institutional holders of CRNX.